MARKET

XERS

XERS

Xeris Biopharma Holdings
NASDAQ
4.805
-0.095
-1.94%
Opening 10:31 05/14 EDT
OPEN
4.960
PREV CLOSE
4.900
HIGH
5.02
LOW
4.800
VOLUME
413.51K
TURNOVER
--
52 WEEK HIGH
6.07
52 WEEK LOW
1.770
MARKET CAP
769.54M
P/E (TTM)
-15.9370
1D
5D
1M
3M
1Y
5Y
1D
Positive Outlook and Strategic Advancements Drive Buy Rating for Xeris Pharmaceuticals
TipRanks · 7h ago
Xeris Pharmaceuticals: Strong Financial Performance and Strategic Growth Drive Buy Rating
TipRanks · 2d ago
Weekly Report: what happened at XERS last week (0505-0509)?
Weekly Report · 2d ago
Xeris Biopharma Is Maintained at Outperform by Oppenheimer
Dow Jones · 4d ago
Oppenheimer Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $7
Benzinga · 4d ago
Xeris Pharmaceuticals (XERS) Gets a Buy from Oppenheimer
TipRanks · 5d ago
Xeris Biopharma price target raised to $7 from $6 at Oppenheimer
TipRanks · 5d ago
XERIS BIOPHARMA HOLDINGS INC. <XERS.O>: OPPENHEIMER RAISES TARGET PRICE TO $7 FROM $6
Reuters · 5d ago
More
About XERS
More
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Recently
Symbol
Price
%Change

Webull offers Xeris Biopharma Holdings Inc stock information, including NASDAQ: XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.